VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET

NAMUR, Belgium, May 9, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that, in conjunction with the filing of its quarterly report on Form 10-Q for the third quarter ended March 31, 2016, it will host a conference call on May 13, 2016, at 8:30 a.m. United States Eastern Time.

Cameron Reynolds, Chief Executive Officer, will host the call and provide an update on recent developments, including details of the ongoing clinical trials of the Company's NuQ® blood-based diagnostic platform. To participate in the call, please dial 1-877-419-6590 (toll-free) in the U.S. and Canada, and 1-719-325-4752 (toll) internationally. The conference ID number for both is 3475419.  A live audio webcast of the conference call will also be available via link on the investor relations page of VolitionRx's corporate website at http://ir.volitionrx.com/.

After the live audio webcast, the event will remain archived on VolitionRx's website for one year.  In addition, a telephone replay of the call will be available until May 27, 2016.  The replay dial-in numbers are 1-877-870-5176 (toll-free) in the U.S. and Canada and 1-858-384-5517 (toll) internationally.  Please use replay pin number 3475419.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The NuQ® tests are based on the science of Nucleosomics® which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

An animation introducing VolitionRx's Nucleosomics® technology can be found at: https://www.youtube.com/watch?v=38dodCpyXf0.

Nucleosomics®, NuQ® and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

Media Contacts

Anita Heward, VolitionRx
a.heward@volitionrx.com 
Telephone: +44 (0) 7756 034243

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (508) 280-6592

Investor Contacts

Scott Powell, VolitionRx
S.Powell@volitionrx.com
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group
lroth@theruthgroup.com            
Telephone: +1 (646) 536-7012

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-schedules-first-quarter-2016-earnings-conference-call-and-business-update-for-friday-may-13-2016-at-830am-et-300264867.html

SOURCE VolitionRx Ltd

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus